Deferasirox API

Name	Deferasirox
Chinese name	地拉罗司
Cas Number	201530-41-8
Source	India
Qualifications	USDMF/-/-/-/-

It is an iron chelating agent product researched and developed by Novartis Pharmaceuticals in Switzerland. It was approved by the FDA in November 2005. It is the first oral iron repellent approved by the FDA for routine use. Used in iron overload patients, it is recommended as the first-line medication for thalassemia iron overload patients over 6 years old in Europe. Delarox has a significant effect in the treatment of iron removal and has good safety. The tolerability increases year by year with time. As the most commonly used iron chelating agent, deferasirox has been shown to be safe and effective in treating children and adults, and its renal safety is good; for patients with low-risk myelodysplastic syndrome (MDS), deferasirox can improve its The overall survival time is better than other iron treatments. According to data from Minai.com, Novartis's global sales of diferasirox exceeded US$1 billion in 2017. Delarox was included in the first batch of encouraged generic drugs in China in 2019.

Hot Tags: deferasirox api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Salmeterol Xinafoate API, Clofarabine API, Apremilast API, Solinasine Succinate API, Troxagliptin Succinate API, Teriflunomide API

• Previous: Idecalcidol API
• Next: Goserelin API